S8822

SB-525334

≥98% (HPLC), solid, ALK5 inhibitor

• Synonim(y): 6-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline
• Wzór empiryczny (zapis Hilla): C₂₁H₂₁N₅
• Numer CAS: 356559-20-1
• Masa cząsteczkowa: 343.42
• UNSPSC Code: 12352200
• PubChem Substance ID: 329824610
• NACRES: NA.77
• MDL number: MFCD11045307
• Assay: ≥98% (HPLC)
• Form: solid

Właściwości

• Nazwa produktu: SB-525334, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: solid
• color: yellow
• solubility: DMSO: ≥20 mg/mL
• originator: GlaxoSmithKline
• storage temp.: 2-8°C
• SMILES string: Cc1cccc(n1)-c2[nH]c(nc2-c3ccc4nccnc4c3)C(C)(C)C
• InChI: 1S/C21H21N5/c1-13-6-5-7-16(24-13)19-18(25-20(26-19)21(2,3)4)14-8-9-15-17(12-14)23-11-10-22-15/h5-12H,1-4H3,(H,25,26)
• InChI key: DKPQHFZUICCZHF-UHFFFAOYSA-N

Opis

Application

SB-525334 was used to study TGFβ1-mediated human trophoblast differentiation.⁷

Biochem/physiol Actions

SB-525334 blocks the activation of Smad2/3 induced by TGFβ1 in renal proximal tubule cells.⁴ The sensitivity of TGFβ1 is decreased by SB-525334 that benefits the pulmonary arterial hypertension condition by reversing the pulmonary arterial pressure.⁵ SB-525334 is reduces the tumor incidence and size of mesenchymal tumors such as uterine leiomyoma.⁶

SB-525334 is a potent activin receptor-like kinase (ALK5)/ type I TGFβ-receptor kinase inhibitor with IC₅₀ = 14.3 nM.

SB-525334 is an ALK5/type I TGFβ-R kinase inhibitor.

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• ppe: dust mask type N95 (US), Eyeshields, Faceshields, Gloves